ISS Believes Company’s Director Nominees Represent an “Unusually Strong” Group of Current and Former Executives From Relevant Fields and Are Best Suited to Continue Overseeing MindMed’s Strategy Concludes There is “No Reasonable Basis” to Question MindMed’s Drug Development Strategy or Third-Party Support From Greenleaf Health Confirms FCM Has Not Made a Compelling Case for Change; […]
Read MoreYou are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
